Trials / Completed
CompletedNCT01248468
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 752 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin, acetaminophen and caffeine | 2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg) |
| DRUG | Sumatriptan | 100 mg Sumatriptan |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-11-25
- Last updated
- 2012-07-30
- Results posted
- 2012-07-30
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01248468. Inclusion in this directory is not an endorsement.